PARP inhibitors are a new area in the treatment of breast cancer
https://doi.org/10.17650/1994-4098-2010-0-4-4-5
Abstract
The paper considers the use of poly(ADP-ribose)-polymerase inhibitors in therapy for breast and ovarian cancer. Particular attention is given to drugs, such as olaparib and BSI-201. It is noted that the emergence of drugs of this class, of course, holds great promise for using remedial measures and gives certain hopes for their optimization.
About the Author
V. P. Letyagin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Пискунова Т.С., Юрова М.Н., Забежинский М.А., Анисимов В.А. Поли(АДФ-рибоза)-полимераза – связь с продолжительностью жизни и канцерогенезом. Успехи геронтол 2007;20(2):82–7.
2. Воскресенский Д.А. Клинико-морфологические особенности больных раком молочной железы с врожденной мутацией в гене CHEK 2. Автореф. дис. ... канд. мед. наук. СПб., 2008.
3. Hudis С. Материалы IV конгресса по раку молочной железы, февраль, 2010, Париж. Здоров Укр 2010; с.1–4.
4. Tentori L., Graziani G. Clonopotentiation by PARP ingibitors in cancer terapy. Pharmacol Res 2005;52(1):25–33.
5. Max S. Wicha. Development of «synthetic lethal» strategies to target BRCA 1-deficient breast cancer. Breast Сancer Res 2009;11(5):1–2.
Review
For citations:
Letyagin V.P. PARP inhibitors are a new area in the treatment of breast cancer. Tumors of female reproductive system. 2010;(4):4-5. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-4-4-5
Views:
599
Email this article 